Literature DB >> 19573265

High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503.

Masatomo Ishikawa1, Muneyuki Sakata, Kenji Ishii, Yuichi Kimura, Keiichi Oda, Jun Toyohara, Jin Wu, Kiichi Ishiwata, Masaomi Iyo, Kenji Hashimoto.   

Abstract

The acetylcholinesterase (AChE) inhibitor donepezil is also a sigma1 receptor agonist. We examined whether donepezil binds to sigma1 receptors in the living human brain after a single oral administration. Dynamic positron emission tomography (PET) data acquisition using the selective sigma1 receptor ligand [11C]SA4503 was performed to evaluate quantitatively the binding of [11C]SA4503 to sigma1 receptors in eight healthy male volunteers. Each subject had a PET scan before and after receiving a single dose of donepezil (5 or 10 mg). The binding potential of [11C]SA4503 was calculated. Doses of 5 mg and 10 mg donepezil bound to sigma1 receptors in the human brain with occupancies of approximately 60% and approximately 75%, respectively, in a dose-dependent manner. This study demonstrated that donepezil binds to sigma1 receptors in the living human brain at therapeutic doses. Therefore, sigma1 receptors may be implicated in the pharmacological mechanism of donepezil in the human brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19573265     DOI: 10.1017/S1461145709990204

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  21 in total

Review 1.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

Review 2.  Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders.

Authors:  Shang-Yi A Tsai; Michael J Pokrass; Neal R Klauer; Nicole E De Credico; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2014-10-21       Impact factor: 6.902

3.  Imaging in Parkinson's disease: time to look below the neck.

Authors:  A Jon Stoessl
Journal:  Brain       Date:  2015-03       Impact factor: 13.501

Review 4.  Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.

Authors:  Linda Nguyen; Brandon P Lucke-Wold; Shona Mookerjee; Nidhi Kaushal; Rae R Matsumoto
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Synthesis and in vitro biological evaluation of carbonyl group-containing analogues for σ1 receptors.

Authors:  Wei Wang; Jinquan Cui; Xiaoxia Lu; Prashanth K Padakanti; Jinbin Xu; Stanley M Parsons; Robert R Luedtke; Nigam P Rath; Zhude Tu
Journal:  J Med Chem       Date:  2011-07-20       Impact factor: 7.446

6.  Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET.

Authors:  Nisha K Ramakrishnan; Anniek K D Visser; Marianne Schepers; Gert Luurtsema; Csaba J Nyakas; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde
Journal:  Psychopharmacology (Berl)       Date:  2014-03-18       Impact factor: 4.530

7.  Radiosynthesis and in vivo evaluation of a novel σ1 selective PET ligand.

Authors:  Hongjun Jin; Jinda Fan; Xiang Zhang; Junfeng Li; Hubert P Flores; Joel S Perlmutter; Stanley M Parsons; Zhude Tu
Journal:  Medchemcomm       Date:  2014-11-01       Impact factor: 3.597

Review 8.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

9.  Cocaine occupancy of sigma1 receptors and dopamine transporters in mice.

Authors:  John R Lever; Emily A Fergason-Cantrell; Lisa D Watkinson; Terry L Carmack; Sarah A Lord; Rong Xu; Dennis K Miller; Susan Z Lever
Journal:  Synapse       Date:  2015-12-24       Impact factor: 2.562

10.  Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases.

Authors:  Tsutomu Furuse; Kenji Hashimoto
Journal:  Ann Gen Psychiatry       Date:  2010-04-24       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.